Development of a highly sensitive bioanalytical assay for the quantification of favipiravir.
Curley, P.; Neary, M.; Arshad, U.; Tatham, L.; Pertinez, H.; Box, H.; Rajoli, R. K. R.; Valentijn, A.; Sharp, J.; Rannard, S.; Owen, A.
Show abstract
Favipiravir (FAV; T-705) has been approved for use as an anti-influenza therapeutic and has reports against a wide range of viruses (e.g., Ebola virus, rabies and norovirus). Most recently FAV has been reported to demonstrate activity against SARS-CoV-2. Repurposing opportunities have been intensively studied with only limited success to date. If successful, repurposing will allow interventions to become more rapidly available than development of new chemical entities. Pre-clinical and clinical investigations of FAV require robust, reproducible and sensitive bioanalytical assay. Here, a liquid chromatography tandem mass spectrometry assay is presented which was linear from 0.78-200 ng/mL Accuracy and precision ranged between 89% and 110%, 101% and 106%, respectively. The presented assay here has applications in both pre-clinical and clinical research and may be used to facilitate further investigations into the application of FAV against SARS-CoV-2.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.